Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology Inc (NQ: VIR )

8.290 -0.310 (-3.60%)
Streaming Delayed Price Updated: 2:57 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
25 Stocks Moving in Wednesday's Pre-Market Session
Gainers 17 Education & Technology Group Inc. (NASDAQ: YQ) rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10... 
Via Benzinga
GSK, Vir's Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered... 
Via Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
3 Vaccine Stocks With Big Opportunities Outside of COVID-19
For most of the past two years, all the focus has been on the coronavirus, but these biotechs have big plans to develop inoculations against other diseases, too. 
Via The Motley Fool
Exposures COVID-19
Why Vir Biotechnology Stock Is Sliding Today
Efficacy results for oral antivirals from Pfizer and Merck are weighing heavily on Vir today. 
Via The Motley Fool
Exposures COVID-19
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
GlaxoSmithKline Drops Research On Otilimab In COVID-19
GlaxoSmithKline Plc (NYSE: GSK), in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in patients who are at least 70 years... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2021
Upgrades According to Wedbush, the prior rating for Regions Financial Corp (NYSE: 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Wells Fargo boosted Bank of America Corporation (NYSE:B... 
Via Benzinga
GlaxoSmithKline: My Top Value Stock For The Week
GSK, one of the biggest pharmaceuticals companies in the world, is seeing a lot of success with new drugs and plenty more in the pipeline. Better yet for would-be investors, the stock is still very... 
Via Talk Markets
Moderna Slapped With Sell Rating Despite CDC Authorization For Covid Boosters
The CDC authorized boosters from J&J, Moderna and a mix-and-match approach. 
Via Investor's Business Daily
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9... 
Via Benzinga
Tesla and Merck Give Investors Some Hope
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate... 
Via Benzinga
54 Biggest Movers From Friday
Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc.... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Biomerica Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 1.49% to 34,346.53 while the NASDAQ rose 0.75% to 14,556.92. The S&P also rose, gaining 1.18% to 4,358.52. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Biomerica (NASDAQ:BMRA) stock moved upwards by 39.33% to $6.27 during Friday's regular session. As of 12:30 EST, Biomerica's stock is trading at a volume... 
Via Benzinga
Merck Stock Surges Into Buy Zone As Covid Pill Reduces Risk Of Death, Hospitalization
Merck said its Covid pill, molnupiravir, cut the risk of death and hospitalization by half. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
Why Vir Biotechnology Stock Is Sinking This Week
Shares fell after an analyst's downgrade. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021
Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE: 
Via Benzinga
Vir Biotechnology Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q2, Vir Biotechnology (NASDAQ:VIR) earned $61.02 million, a 138.46% increase from the preceding quarter. Vir Biotechnology also posted a total of... 
Via Benzinga
Now May Be the Big Moment for These 2 COVID Stocks
Their products are seeing a surge in demand. 
Via The Motley Fool
Exposures COVID-19
9 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Vir Biotech-GSK's COVID-19 Treatment Wins Provisional Approval In Australia
The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's (NASDAQ: VIR) for sotrovimab,... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.